936960.fig.004
Figure 4: Percentage of the patients relapsing during the follow-up treatment free-period (at 3, 6, and 10 weeks) after 12 weeks treatment with placebo or otilonium bromide. * as compared to respective placebo group. From OBIS trial [9].